Vom Dorp F, Börgermann C, Rose A, Becker M, Rübben H
Klinik und Poliklinik für Urologie, Universitätsklinikum, Hufelandstrasse 55, 45122 Essen, Deutschland.
Urologe A. 2008 Oct;47(10):1311-4. doi: 10.1007/s00120-008-1747-9.
The current therapy concept for metastatic bladder cancer is chemotherapy with gemcitabine and cisplatin as the first line protocol. Within the last 20 years no real progress could be achieved; the median survival is 14 months, though many different protocols have been tested. Expression analyses of growth factor receptors in human tumor tissue showed that expression of certain receptors is correlated with a severe clinical course.For many of these growth factor receptors pharmacological inhibitors are available in order to perform targeted therapy. The following review gives a survey of current studies on targeted therapy of metastatic bladder carcinoma.
转移性膀胱癌目前的治疗理念是以吉西他滨和顺铂联合化疗作为一线方案。在过去20年里,并未取得实质性进展;尽管已经测试了许多不同的方案,但中位生存期仍为14个月。对人类肿瘤组织中生长因子受体的表达分析表明,某些受体的表达与严重的临床病程相关。对于许多这类生长因子受体,有相应的药理学抑制剂可用于开展靶向治疗。以下综述概述了目前关于转移性膀胱癌靶向治疗的研究情况。